Effects of aliskiren on hemodynamic parametersin daunorubicin -induced acute cardiomyopathy in rats
Daunorubicin ((DNR)) used in oncological practice against a wide variety of solid organ tumors and hematologic malignancies, including leukemia, lymphoma, breast cancer, lung cancer, multiple myeloma and sarcoma. however clinical use of this agent is limited due to cardiomyopathy and cardiac heart failure. one of the important player in the development of cardic hypertrophy and reperfusion injury is renin-angiotensin system. Aliskiren (ALK) a recent drug of a direct inhibitor of the renin enzyme. It Protect cardiomyopathy by the inhibition of the renin activity. Present study is towards the evaluation of protective effcets of ALK 50 and 100 mg/kg/day in rats. The systolic, diastolic, mean BP and heart rate were significantly (P< 0.01) increased in DNR control group as compared to normal control group. Thus the results provide clear evidence that the ALK pretreatment offered significant protection against DNR-induced Hemodynamic parameters changes.
Keywords: Daunorubicin, Cardiomyopathy, Aliskiren, Telmisartan and Hemodynamic parameters
2. Buza V, Rajagopalan B, Curtis AB. Cancer Treatment–Induced Arrhythmias Focus on Chemotherapy and Targeted Therapies. Circulation: Arrhythm Electrophysiol, 2017; 10:e005443
3. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. European Heart Journal, 2013; 34:1102–1111
4. Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti, TA., Riggs WK. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. frontiers in genetics, 2013; 4:231
5. Sawyer DB., Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res, 1999; 84(3):257–265
6. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. BLOOD, 2018; 98:4
7. Guzy J, Kunir J, Marekova M, Chavkova Z, Dubayova K, Ova GM, Mirossay L, Moj.JI. Effect of Quercetin on Daunorubicin-Induced HeartMitochondria Changes in Rats. Physiol. Res. 2003; 52:773-780
8. Al-Kuraishy HM, Al-Gareeb AI. Potential Effects of Pomegranate on Lipid Peroxidation and Pro-inflammatory Changes in Daunorubicininduced Cardiotoxicity in Rats. Int J Prev Med. 2016; (20)7:85
9. Kasireddy GR, Mohsin M, Ravinder T, Chinnam P. Evaluation of Cardioprotective effect of Nigella Sativa Oil in Daunorubicin Induced Cardiotoxicity in Albino Rats. Journal of Chalmeda Anand Rao Institute of Medical Sciences, 2014; 7(1):14-16
10. Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Suzuki K., Kodama M, Aizawa Y, Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology, 2010; 274(1-3):18-26
11. Zhang J, Cui X, Yan Y, Li M, Yang Y, Wang J, Zhang J. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. Am J Transl Res 2016; 8(7):2862-2875
12. Barrera G. Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. International Scholarly Research Network Oncology, 2012; Article ID 137289, 21
13. Deavall DG, Martin EA, Horner JM, Roberts R. Drug-Induced Oxidative Stress and Toxicity. Journal of Toxicology, 2012; Article ID 645460, 13
14. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta, 2014; 1845(1):84–89
15. Rao VA. Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications. Antioxidants & redox signaling, 2013; 18(8)
16. Taskin E, Kindap EK, Ozdogan K, Aycan MB, Dursun N, Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II. Cytotechnology, 2016; 68:33–43
17. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, Yamane T, Hino M. Notable Effects of Angiotensin II Receptor Blocker, Valsartan, on Acute Cardiotoxic Changes after Standard Chemotherapy with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. CANCER, 2005; 104:11
18. Rashikh A , Ahmad SA , Pillai KK, Kohli K , Najmi AK. Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy. Biomedicine & Pharmacotherapy, 2012; 66:138–143
19. Druhan L, Fasan F and Copelan OR. Acute Heart Failure in a Patient with Acute Myeloid Leukemia following Daunorubicin Treatment: a Case Report. Journal of Leukemia, 2015; 3:2
20. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 2012; 52:1213–1225
21. Shafik AN, Khodei, MM, Fadel MS. Animal study of Anthracycline-induced Cardiotoxicity and Nephrotoxicity and Evaluation of Protective Agents. Journal of Cancer Science & Therapy. 2011; 3(5):96-103
22. Pimentel DR, Amin JK, Xiao L, Miller T, Viereck J, Oliver-Krasinski J, Baliga R, Wang J, Siwik DA, Singh K, Pagano P, Colucci WS, Sawyer DB. Reactive Oxygen Species Mediate Amplitude-Dependent Hypertrophic and Apoptotic Responses to Mechanical Stretch in Cardiac Myocytes. Circulation Research, 2001.
23. Qin F, Rounds NK, Mao W, Kawai K, Liang C. Antioxidant vitamins prevent cardiomyocyte apoptosis produced by norepinephrine infusion in ferrets. Cardiovascular Research, 2001; 51:736–748
24. Minami J, Ishimitsu T, Matsuoka H. Pretreatment Plasma Renin Activity Levels Correlate With the Blood Pressure Response to Telmisartan in Essential Hypertension. American Journal of Hypertension, 2008; 21(1):10–13
25. Wu J, Kraja AT, Oberman A, Lewis CE, Ellison RC, Arnett DK, Heiss G, Lalouel J, Turner ST, Hunt SC, Province MA and Rao DC. A Summary of the Effects of Antihypertensive Medications on Measured Blood Pressure. American Journal of Hypertension, 2005; 18:935–942
26. Siragy HM, Carey RM. Role of the Intrarenal Renin-Angiotensin- Aldosterone System in Chronic Kidney Disease. Am J Nephrol 2010; 31:541–550.
27. Munoz-Durango N, Fuentes CA, CastilloAE, Gonzalez-Gomez LM, Vecchiola A, Fardella CE and Kalergis AM. Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension. International Journal of Molecular Science, 2016; 17:797
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).